Table of Content

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
3.2.2. GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
3.2.3. BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
3.2.4. DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION

4. MARKET DYNAMICS
4.1. MARKET SCOPE & DEFINITION
4.2. MARKET DRIVERS
4.2.1. ADOPTION OF WESTERN LIFESTYLES IN DEVELOPING REGIONS
4.2.2. GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
4.2.3. ENCOURAGEMENT FOR BIOMARKER DEVELOPMENT BY FDA
4.2.4. IMPROVED PRECISION AND SPEED OF DIAGNOSIS
4.2.5. HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
4.2.6. DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
4.2.7. GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
4.2.8. TECHNOLOGICAL ADVANCEMENTS
4.2.9. GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
4.3. MARKET RESTRAINTS
4.3.1. POOR COMPENSATION STRUCTURES
4.3.2. LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
4.3.3. TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
4.3.4. HIGH COST OF DRUG DEVELOPMENT
4.3.5. UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
4.4. MARKET OPPORTUNITIES
4.4.1. WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
4.4.2. SUPPORTS ON BIOMARKERS TEST
4.4.3. GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
4.4.4. ADVANCEMENT OF CANCER DRUGS RESEARCH
4.5. MARKET CHALLENGES
4.5.1. LACKING ACCEPTANCE OF THE CANCER BIOMARKER
4.5.2. UNFAVORABLE COMPENSATION SITUATION
4.5.3. HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
4.5.4. RIGOROUS REGULATORY AGENDA
4.5.5. DEARTH OF SKILFUL WORKERS

5. MARKET BY PROFILING TECHNOLOGY
5.1. OMIC TECHNOLOGY
5.1.1. GENOMICS
5.1.1.1. NEXT-GENERATION SEQUENCING (NGS)
5.1.1.2. MICROARRAY
5.1.1.3. POLYMERASE CHAIN REACTION (PCR)
5.1.2. PROTEOMICS
5.1.2.1. MASS SPECTROMETRY
5.1.2.2. 2D GEL ELECTROPHORESIS
5.1.2.3. PROTEIN MICROARRAY TECHNOLOGY
5.1.2.4. ANTIBODY ARRAY TECHNOLOGY
5.1.2.5. PEPTIDE ARRAY TECHNOLOGY
5.1.3. OTHER OMIC TECHNOLOGIES
5.1.3.1. METABOLOMICS
5.1.3.2. GLYCOMICS
5.2. IMAGING TECHNOLOGIES
5.2.1. MAGNETIC RESONANCE IMAGING (MRI)
5.2.2. POSITRON EMISSION TOMOGRAPHY (PET)
5.2.3. COMPUTED TOMOGRAPHY
5.2.4. MAMMOGRAPHY
5.2.5. ULTRASOUND
5.3. IMMUNOASSAYS
5.3.1. IMMUNOHISTOCHEMISTRY (IHC) TESTS
5.3.2. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
5.3.3. FLOW CYTOMETRY
5.4. CYTOGENETIC-BASED TESTS
5.4.1. IN SITU HYBRIDIZATION
5.4.2. OTHERS CYTOGENETIC-BASED TESTS

6. MARKET BY BIOMARKER
6.1. GENETIC BIOMARKERS
6.2. PROTEIN BIOMARKERS
6.3. GLYCO BIOMARKERS

7. MARKET BY CANCER TYPE
7.1. LUNG CANCER
7.2. BREAST CANCER
7.3. COLORECTAL CANCER
7.4. PROSTATE CANCER
7.5. STOMACH CANCER
7.6. OTHERS CANCER TYPE

8. MARKET BY APPLICATION
8.1. DIAGNOSTICS
8.2. DRUG DISCOVERY AND DEVELOPMENT
8.3. PROGNOSTICS
8.4. RISK ASSESSMENT
8.5. OTHER APPLICATION

9. KEY ANALYTICS
9.1. PORTER’S FIVE FORCE ANALYSIS
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCT
9.1.3. BARGAINING POWER OF BUYER
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. KEY BUYING CRITERIA
9.2.1. PRICING
9.2.2. EFFICACY
9.2.3. APPLICATION AND EFFECTIVENESS
9.3. PATENT ANALYSIS
9.4. ONCOLOGY DRUGS APPROVALS BY THE FDA
9.5. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. THE UNITED STATES
10.1.2. CANADA
10.2. EUROPE
10.2.1. GERMANY
10.2.2. THE UNITED KINGDOM
10.2.3. FRANCE
10.2.4. ITALY
10.2.5. SPAIN
10.2.6. REST OF EUROPE
10.3. ASIA PACIFIC
10.3.1. CHINA
10.3.2. INDIA
10.3.3. JAPAN
10.3.4. SOUTH KOREA
10.3.5. AUSTRALIA
10.3.6. REST OF APAC
10.4. REST OF WORLD
10.4.1. LATIN AMERICA
10.4.2. MIDDLE EAST AND AFRICA

11. COMPETITIVE LANDSCAPE
11.1. MARKET SHARE ANALYSIS
11.2. COMPANY PROFILES
11.2.1. ABBOTT LABORATORIES
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCT PORTFOLIO
11.2.1.3. SCOT ANALYSIS
11.2.1.4. STRATEGIC INITIATIVES
11.2.2. AGENDIA N.V.
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCT PORTFOLIO
11.2.2.3. SCOT ANALYSIS
11.2.2.4. STRATEGIC INITIATIVES
11.2.3. AGILENT TECHNOLOGIES, INC.
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCT PORTFOLIO
11.2.3.3. SCOT ANALYSIS
11.2.3.4. STRATEGIC INITIATIVES
11.2.4. AUREON BIOSCIENCES, INC
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCT PORTFOLIO
11.2.4.3. SCOT ANALYSIS
11.2.4.4. STRATEGIC INITIATIVES
11.2.5. ASTELLAS PHARMA INC.
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCT PORTFOLIO
11.2.5.3. SCOT ANALYSIS
11.2.5.4. STRATEGIC INITIATIVES
11.2.6. BECKMAN COULTER
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCT PORTFOLIO
11.2.6.3. SCOT ANALYSIS
11.2.6.4. STRATEGIC INITIATIVES
11.2.7. BECTON DICKINSON AND COMPANY
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCT PORTFOLIO
11.2.7.3. SCOT ANALYSIS
11.2.7.4. STRATEGIC INITIATIVES
11.2.8. BRISTOL-MYERS SQUIBB
11.2.8.1. COMPANY PROFILES
11.2.8.2. PRODUCT PORTFOLIO
11.2.8.3. SCOT ANALYSIS
11.2.8.4. STRATEGIC INITIATIVES
11.2.9. CELGENE CORPORATION
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCT PORTFOLIO
11.2.9.3. SCOT ANALYSIS
11.2.9.4. STRATEGIC INITIATIVES
11.2.10. CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCT PORTFOLIO
11.2.10.3. SCOT ANALYSIS
11.2.10.4. STRATEGIC INITIATIVES
11.2.11. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCT PORTFOLIO
11.2.11.3. SCOT ANALYSIS
11.2.11.4. STRATEGIC INITIATIVES
11.2.12. ILLUMINA, INC.
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCT PORTFOLIO
11.2.12.3. SCOT ANALYSIS
11.2.12.4. STRATEGIC INITIATIVES
11.2.13. ROCHE DIAGNOSTICS LTD
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCT PORTFOLIO
11.2.13.3. SCOT ANALYSIS
11.2.13.4. STRATEGIC INITIATIVES
11.2.14. SANOFI
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCTS PORTFOLIO
11.2.14.3. SWOT ANALYSIS
11.2.14.4. STRATEGIC INITIATIVES
11.2.15. QIAGEN N.V.
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCT PORTFOLIO
11.2.15.3. SCOT ANALYSIS
11.2.15.4. STRATEGIC INITIATIVES










TABLE LIST
TABLE 1 GLOBAL CANCER BIOMARKER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 2 RECENT RESEARCH ON BIOMARKERS
TABLE 3 LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS
TABLE 4 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS
TABLE 5 MEDICAL TOURISM PRICES IN US DOLLAR
TABLE 6 GLOBAL CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 7 GLOBAL OMIC TECHNOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 8 GLOBAL OMIC TECHNOLOGY MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 9 GLOBAL GENOMICS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 10 GLOBAL PROTEOMICS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 11 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 12 GLOBAL IMAGING TECHNOLOGIES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 13 GLOBAL IMAGING TECHNOLOGIES MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 14 GLOBAL IMMUNOASSAYS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 15 GLOBAL IMMUNOASSAYS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 16 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 17 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 18 GLOBAL CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)
TABLE 19 GLOBAL GENETIC BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 20 GLOBAL PROTEIN BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 21 GLOBAL GLYCO BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 22 GLOBAL CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)
TABLE 23 GLOBAL LUNG CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 24 GLOBAL BREAST CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 25 GLOBAL COLORECTAL CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 26 GLOBAL PROSTATE CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 27 GLOBAL STOMACH CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 28 GLOBAL OTHERS CANCER TYPE MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 29 GLOBAL CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 30 GLOBAL DIAGNOSTICS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 31 GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 32 GLOBAL PROGNOSTICS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 33 GLOBAL RISK ASSESSMENT MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 34 GLOBAL OTHER APPLICATION MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 35 PATENT PRODUCTS WITH THE EXPIRY DATE
TABLE 36 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017
TABLE 37 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017
TABLE 38 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017
TABLE 39 GLOBAL CANCER BIOMARKER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 40 NORTH AMERICA CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 41 EUROPE CANCER BIOMARKER MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 42 ASIA PACIFIC CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 43 STATE-WISE DISTRIBUTION OF CANCER IN INDIA
TABLE 44 ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017
TABLE 45 REST OF WORLD CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)



FIGURES LIST
FIGURE 1 NUMBER OF PEOPLE LIVING WITH CANCER ACROSS THE GLOBE FOR PERIOD 2012-2020 (MILLION)
FIGURE 2 GLOBAL CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 3 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING
FIGURE 4 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)
FIGURE 5 LIST OF CLEARED OR APPROVED COMPANION DIAGNOSTIC DEVICES (IMAGING TOOLS AND IN VITRO) BY FDA
FIGURE 6 GLOBAL CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)
FIGURE 7 GLOBAL GENOMICS MARKET BY NEXT-GENERATION SEQUENCING (NGS) 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL GENOMICS MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL GENOMICS MARKET BY POLYMERASE CHAIN REACTION (PCR) 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL PROTEOMICS MARKET BY MASS SPECTROMETRY 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL PROTEOMICS MARKET BY 2D GEL ELECTROPHORESIS 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL PROTEOMICS MARKET BY PROTEIN MICROARRAY TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL PROTEOMICS MARKET BY ANTIBODY ARRAY TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL PROTEOMICS MARKET BY PEPTIDE ARRAY TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY METABOLOMICS 2019-2027 ($ MILLION)
FIGURE 16 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY GLYCOMICS 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL IMAGING TECHNOLOGIES MARKET BY MAGNETIC RESONANCE IMAGING(MRI) 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL IMAGING TECHNOLOGIES MARKET BY POSITRON EMISSION TOMOGRAPHY (PET) 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL IMAGING TECHNOLOGIES MARKET BY COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL IMAGING TECHNOLOGIES MARKET BY MAMMOGRAPHY 2019-2027 ($ MILLION)
FIGURE 21 GLOBAL IMAGING TECHNOLOGIES MARKET BY ULTRASOUND 2019-2027 ($ MILLION)
FIGURE 22 GLOBAL IMMUNOASSAYS MARKET BY IMMUNOHISTOCHEMISTRY(IHC) TESTS 2019-2027 ($ MILLION)
FIGURE 23 GLOBAL IMMUNOASSAYS MARKET BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 2019-2027 ($ MILLION)
FIGURE 24 GLOBAL IMMUNOASSAYS MARKET BY FLOW CYTOMETRY 2019-2027 ($ MILLION)
FIGURE 25 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY IN SITU HYBRIDIZATION 2019-2027 ($ MILLION)
FIGURE 26 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY OTHERS CYTOGENETICS-BASED TESTS 2019-2027 ($ MILLION)
FIGURE 27 GLOBAL CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)
FIGURE 28 GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 29 GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 30 PORTER’S FIVE FORCE ANALYSIS
FIGURE 31 GLOBAL CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 32 THE UNITED STATES CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 33 PROPORTION OF DEATH CAUSED BY CANCER AND OTHER DISEASE IN CANADA (%)
FIGURE 34 CANADA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 35 GERMANY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 36 THE UNITED KINGDOM CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 37 FRANCE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 38 ITALY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 39 SPAIN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 40 REST OF EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 41 CHINA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 42 INDIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 43 JAPAN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 44 SOUTH KOREA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 45 AUSTRALIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 46 REST OF APAC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 47 LATIN AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 48 MIDDLE EAST AND AFRICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)



List of Figures


FIGURES LIST
FIGURE 1 NUMBER OF PEOPLE LIVING WITH CANCER ACROSS THE GLOBE FOR PERIOD 2012-2020 (MILLION)
FIGURE 2 GLOBAL CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 3 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING
FIGURE 4 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)
FIGURE 5 LIST OF CLEARED OR APPROVED COMPANION DIAGNOSTIC DEVICES (IMAGING TOOLS AND IN VITRO) BY FDA
FIGURE 6 GLOBAL CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)
FIGURE 7 GLOBAL GENOMICS MARKET BY NEXT-GENERATION SEQUENCING (NGS) 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL GENOMICS MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL GENOMICS MARKET BY POLYMERASE CHAIN REACTION (PCR) 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL PROTEOMICS MARKET BY MASS SPECTROMETRY 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL PROTEOMICS MARKET BY 2D GEL ELECTROPHORESIS 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL PROTEOMICS MARKET BY PROTEIN MICROARRAY TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL PROTEOMICS MARKET BY ANTIBODY ARRAY TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL PROTEOMICS MARKET BY PEPTIDE ARRAY TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY METABOLOMICS 2019-2027 ($ MILLION)
FIGURE 16 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY GLYCOMICS 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL IMAGING TECHNOLOGIES MARKET BY MAGNETIC RESONANCE IMAGING(MRI) 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL IMAGING TECHNOLOGIES MARKET BY POSITRON EMISSION TOMOGRAPHY (PET) 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL IMAGING TECHNOLOGIES MARKET BY COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL IMAGING TECHNOLOGIES MARKET BY MAMMOGRAPHY 2019-2027 ($ MILLION)
FIGURE 21 GLOBAL IMAGING TECHNOLOGIES MARKET BY ULTRASOUND 2019-2027 ($ MILLION)
FIGURE 22 GLOBAL IMMUNOASSAYS MARKET BY IMMUNOHISTOCHEMISTRY(IHC) TESTS 2019-2027 ($ MILLION)
FIGURE 23 GLOBAL IMMUNOASSAYS MARKET BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 2019-2027 ($ MILLION)
FIGURE 24 GLOBAL IMMUNOASSAYS MARKET BY FLOW CYTOMETRY 2019-2027 ($ MILLION)
FIGURE 25 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY IN SITU HYBRIDIZATION 2019-2027 ($ MILLION)
FIGURE 26 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY OTHERS CYTOGENETICS-BASED TESTS 2019-2027 ($ MILLION)
FIGURE 27 GLOBAL CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)
FIGURE 28 GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 29 GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 30 PORTER’S FIVE FORCE ANALYSIS
FIGURE 31 GLOBAL CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 32 THE UNITED STATES CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 33 PROPORTION OF DEATH CAUSED BY CANCER AND OTHER DISEASE IN CANADA (%)
FIGURE 34 CANADA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 35 GERMANY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 36 THE UNITED KINGDOM CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 37 FRANCE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 38 ITALY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 39 SPAIN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 40 REST OF EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 41 CHINA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 42 INDIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 43 JAPAN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 44 SOUTH KOREA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 45 AUSTRALIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 46 REST OF APAC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 47 LATIN AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 48 MIDDLE EAST AND AFRICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)
 

 

List of Tables


TABLE LIST
TABLE 1 GLOBAL CANCER BIOMARKER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 2 RECENT RESEARCH ON BIOMARKERS
TABLE 3 LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS
TABLE 4 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS
TABLE 5 MEDICAL TOURISM PRICES IN US DOLLAR
TABLE 6 GLOBAL CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 7 GLOBAL OMIC TECHNOLOGY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 8 GLOBAL OMIC TECHNOLOGY MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 9 GLOBAL GENOMICS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 10 GLOBAL PROTEOMICS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 11 GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 12 GLOBAL IMAGING TECHNOLOGIES MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 13 GLOBAL IMAGING TECHNOLOGIES MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 14 GLOBAL IMMUNOASSAYS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 15 GLOBAL IMMUNOASSAYS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 16 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 17 GLOBAL CYTOGENETICS-BASED TESTS MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 18 GLOBAL CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)
TABLE 19 GLOBAL GENETIC BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 20 GLOBAL PROTEIN BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 21 GLOBAL GLYCO BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 22 GLOBAL CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)
TABLE 23 GLOBAL LUNG CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 24 GLOBAL BREAST CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 25 GLOBAL COLORECTAL CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 26 GLOBAL PROSTATE CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 27 GLOBAL STOMACH CANCER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 28 GLOBAL OTHERS CANCER TYPE MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 29 GLOBAL CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 30 GLOBAL DIAGNOSTICS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 31 GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 32 GLOBAL PROGNOSTICS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 33 GLOBAL RISK ASSESSMENT MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 34 GLOBAL OTHER APPLICATION MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 35 PATENT PRODUCTS WITH THE EXPIRY DATE
TABLE 36 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017
TABLE 37 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017
TABLE 38 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017
TABLE 39 GLOBAL CANCER BIOMARKER MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 40 NORTH AMERICA CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 41 EUROPE CANCER BIOMARKER MARKET BY COUNTRY 2018-2026 ($ MILLION)
TABLE 42 ASIA PACIFIC CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 43 STATE-WISE DISTRIBUTION OF CANCER IN INDIA
TABLE 44 ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017
TABLE 45 REST OF WORLD CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)